Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polysomy 17 and HER-2 Amplification: True, True, and Unrelated

16 Sept 2008

Abstract excerpt

Approximately 25% of breast cancers overexpress the human epidermal growth factor receptor 2 (HER-2) protein, usually as a result of high copy number of its gene (amplification) on chromosome 17q12-21. HER-2 signaling promotes cell proliferation, and overexpression or gene amplification are associated with poor prognosis. 1 Inviewofthis,trastuzumab(Herceptin;Genentech,SouthSan Francisco, CA), a humanized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18794542
DOI: 10.1200/jco.2008.17.2684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedPMID 18794542Read ↗

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.Semantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.Semantic proximity Read ↗

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read ↗

HER2: Biology, Detection, and Clinical ImplicationsSemantic proximity Read ↗

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.Semantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort studySemantic proximity Read ↗

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare eventSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.